The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ou, Zhanhui ^a   Niu, Xiaohua ^a   He, Wenyin ^a   Chen, Yuchang ^a   Song, Bing ^a   Xian, Yexing ^a   Fan, Di ^a   Tang, Daolin ^a,b   Sun, Xiaofang ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN BETA CHAIN; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL; BETA THALASSEMIA; CELL DIFFERENTIATION; CRISPR CAS SYSTEM; CYTOLOGY; DEFICIENCY; FEMALE; GENE EDITING; GENE EXPRESSION; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMOLOGOUS RECOMBINATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; WHOLE BODY RADIATION;

ANIMALS; BETA-GLOBINS; BETA-THALASSEMIA; CELL DIFFERENTIATION; CRISPR-CAS SYSTEMS; FEMALE; GENE EDITING; GENE EXPRESSION; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; WHOLE-BODY IRRADIATION;

EID: 84984927508     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32463     Document Type: Article

References (39)

1. Cao, A. & Kan, Y. W. The prevention of thalassemia. Cold Spring Harbor perspectives in medicine 3, a011775, doi: 10.1101/cshperspect. a011775 (2013).
2. Rund, D. & Rachmilewitz, E. Beta-thalassemia. The New England journal of medicine 353, 1135-1146, doi: 10.1056/NEJMra050436 (2005).
3. Galanello, R. & Origa, R. Beta-thalassemia. Orphanet journal of rare diseases 5, 11, doi: 10.1186/1750-1172-5-11 (2010).
4. Xu, X. M. et al. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. Journal of clinical pathology 57, 517-522 (2004).
5. Ou, Z., Li, Q., Liu, W. & Sun, X. Elevated hemoglobin A2 as a marker for beta-thalassemia trait in pregnant women. The Tohoku journal of experimental medicine 223, 223-226 (2011).
6. Ntaios, G. et al. Discrimination indices as screening tests for beta-thalassemic trait. Annals of hematology 86, 487-491, doi: 10.1007/s00277-007-0302-x (2007).
7. Sirichotiyakul, S., Wanapirak, C., Srisupundit, K., Luewan, S. & Tongsong, T. A comparison of the accuracy of the corpuscular fragility and mean corpuscular volume tests for the alpha-thalassemia 1 and beta-thalassemia traits. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 107, 26-29, doi: 10.1016/j. ijgo.2009.05.012 (2009).
8. Weatherall, D. J. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Annals of the New York Academy of Sciences 1202, 17-23, doi: 10.1111/j.1749-6632.2010.05546.x (2010).
9. Isgro, A., Gaziev, J., Sodani, P. & Lucarelli, G. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Annals of the New York Academy of Sciences 1202, 149-154, doi: 10.1111/j.1749-6632.2010.05543.x (2010).
10. Boulad, F., Riviere, I. & Sadelain, M. Gene therapy for homozygous beta-thalassemia. Is it a reality? Hemoglobin 33 Suppl 1, S188-196, doi: 10.3109/03630260903351866 (2009).
11. Lucarelli, G. et al. Bone marrow transplantation in adult thalassemic patients. Blood 93, 1164-1167 (1999).
12. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676, doi: 10.1016/j.cell.2006.07.024 (2006).
13. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872, doi: 10.1016/j.cell.2007.11.019 (2007).
14. Choi, K. D. et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem cells 27, 559-567, doi: 10.1634/stemcells.2008-0922 (2009).
15. Loh, Y. H. et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nature genetics 38, 431-440, doi: 10.1038/ng1760 (2006).
16. Ye, L. et al. Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. Stem cells translational medicine 2, 558-566, doi: 10.5966/sctm.2013-0006 (2013).
17. Song, B. et al. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem cells and development 24, 1053-1065, doi: 10.1089/scd.2014.0347 (2015).
18. Makarova, K. S. et al. Evolution and classification of the CRISPR-Cas systems. Nature reviews. Microbiology 9, 467-477, doi: 10.1038/nrmicro2577 (2011).
19. Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nature methods 10, 957-963, doi: 10.1038/nmeth.2649 (2013).
20. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, doi: 10.1126/science.1231143 (2013).
21. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918, doi: 10.1016/j.cell.2013.04.025 (2013).
22. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821, doi: 10.1126/science.1225829 (2012).
23. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826, doi: 10.1126/science.1232033 (2013).
24. Gratz, S. J. et al. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics 194, 1029-1035, doi: 10.1534/genetics.113.152710 (2013).
25. Hanna, J. et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920-1923, doi: 10.1126/science.1152092 (2007).
26. Wang, Y. et al. Genetic correction of beta-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell research 22, 637-648, doi: 10.1038/cr.2012.23 (2012).
27. Ma, N. et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. The Journal of biological chemistry 288, 34671-34679, doi: 10.1074/jbc.M113.496174 (2013).
28. Huang, X. et al. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. Stem cells 33, 1470-1479, doi: 10.1002/stem.1969 (2015).
29. Xie, F. et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome research 24, 1526-1533, doi: 10.1101/gr.173427.114 (2014).
30. Niu, X. et al. Combining single-strand oligodeoxynucleotides and CRISPR/Cas9 to correct gene mutations in Beta-thalassemiainduced Pluripotent Stem Cells. The Journal of biological chemistry, doi: 10.1074/jbc.M116.719237 (2016).
31. Kashyap, V. et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem cells and development 18, 1093-1108, doi: 10.1089/scd.2009.0113 (2009).
32. Fong, C. Y., Peh, G. S., Gauthaman, K. & Bongso, A. Separation of SSEA-4 and TRA-1-60 labelled undifferentiated human embryonic stem cells from a heterogeneous cell population using magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS). Stem cell reviews 5, 72-80, doi: 10.1007/s12015-009-9054-4 (2009).
33. Ledran, M. H. et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell stem cell 3, 85-98, doi: 10.1016/j.stem.2008.06.001 (2008).
34. Schwank, G. et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell stem cell 13, 653-658, doi: 10.1016/j.stem.2013.11.002 (2013).
35. Sakuma, T., Nishikawa, A., Kume, S., Chayama, K. & Yamamoto, T. Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system. Scientific reports 4, 5400, doi: 10.1038/srep05400 (2014).
36. Ye, W. et al. Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. Journal of hematology & oncology 8, 59, doi: 10.1186/s13045-015-0156-y (2015).
37. Fan, Y., Luo, Y., Chen, X. & Sun, X. A modified culture medium increases blastocyst formation and the efficiency of human embryonic stem cell derivation from poor-quality embryos. The Journal of reproduction and development 56, 533-539 (2010).
38. Tang, D. et al. Endogenous HMGB1 regulates autophagy. The Journal of cell biology 190, 881-892, doi: 10.1083/jcb.200911078 (2010).
39. Sun, X. et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64, 488-500, doi: 10.1002/hep.28574 (2016).